Unravel Biosciences, Inc. — Form D
Unravel Biosciences, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2023-03-09. The offering totals $2.0M, of which $500K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-03-09
- Form: D
- Accession: 0001876967-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.0M
- Amount sold: $500K
- Remaining: $1.5M
- Investors: 4
- Date of first sale: 2023-02-22
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-475306
Issuer
- Name: Unravel Biosciences, Inc.
- CIK: 0001876967
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 100 WILLIAM T. MORRISSEY BLVD., BOSTON, MA, 02125
- Phone: 510-984-2317
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Donald Ingber | Director | Boston, MA |
| Richard Novak | Director | Boston, MA |
| Frederic Vigneault | Director | Boston, MA |
| Richard Novak | Executive Officer | Boston, MA |
| Frederic Vigneault | Executive Officer | Boston, MA |
| Lewis Geffen | Executive Officer | Cambridge, MA |
Other filings by this issuer (1)
More